Dexmedetomidine in the Treatment of Agitation Associated With Bipolar Disorder
Study sponsor: BioXcel Therapeutics Inc
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-05-21Actual
Enrollment · participants380Actual
Source updated2026-08-11Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.